IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Venkatraman, et al. Confirmation No.: 2177

Serial No. : 10/611,531 Art Unit: 1611

Filed : June 30, 2003 Examiner: I. A. D. Ghali

For : THERMOPLASTIC DRUG DELIVERY DEVICES COMPRISING A

POLYURETHANE DRUG RESERVOIR

I hereby certify that this correspondence is being transmitted via The Office electronic filing system in accordance with 37 CFR 1.6(a)(4)

September 30, 2010 (Date of Transmission)

Anna M. Pignaloni
(Name of applicant, assignee, or Registered Representative, or Transmitter)

/Anna M. Pignaloni/ (Signature)

September 30, 2010 (Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 30, 2003 and April 25, 2005

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement
is being filed either within three months of the filing date of the above-identified national
application (other than a continued prosecution application under §1.53(d)), within three
months of the date of entry into the national stage of the above identified application as
set forth in $\S 1.491$, or before the mailing date of a first Office Action on the merits of the
above-identified application, or before the mailing date of a first Office Action after the
filing of a request for continued examination under §1.114, no additional fee is required.
☐ In accordance with §1.129(a), this Information Disclosure Statement is
being filed in connection with $\hfill\square$ the first or $\hfill\square$ second After Final Submission, therefore:
☐ Statement in Accordance with §1.97(e) (attached); or
☐ Please charge Deposit Account No. 10-0750/ / the fee of
<u>\$180.00</u> as set forth in §1.17(p).
☐ In accordance with §1.97(c), this Information Disclosure Statement is
being filed after the period set forth in §1.97(b) above but before the mailing date of
either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action
that otherwise closes prosecution and that it is accompanied by one of:
☐ Statement in Accordance with §1.97(e) (attached); or
Please charge Deposit Account No. 10-0750/ / the fee of
\$180.00 as set forth in §1.17(p).
☐ In accordance with §1.97(d), this Information Disclosure Statement is
being filed after the mailing date of either a Final Action under §1.113 or a Notice of
Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby

petition(s) for	consid	eration of this Information Disclosure Statement. Included are:	
Statement in .	Accord	ance with §1.97(e) as set forth below and the fee of $$180.00$ as set	
forth in §1.17((p).		
are enclosed	•	s of each of the references listed on the attached Form PTO-1449 th.	
☐ herewith EXC	•	s of references listed on the attached Form PTO-1449 are enclosed HAT:	
		In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, certain copies are not enclosed herewith. Copies of reference that have been made of record in U.S. Serial Number filed, are not supplied herewith.	
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
application puenclosed, it is international a	ccordar ublication becau applicar	s of only foreign patent documents and non-patent literature are not with 37 CFR 1.98 (a)(2). If any U.S. patents and U.S. patent ons are listed on the attached Form PTO-1449 and are not se this U.S. patent application was filed after June 30, 2003 or this tion has entered the national stage under 35 USC 371 after June 30 waiver of requirement under 37 CFR 1.98(a)(2)(ii)).	
	There	are no listed references which are not in the English language.	
	Concerning references which are not in the English language, the		
following com	ments	are made:	

JP-A-9-188618 English Abstract JP-A-62-47372 English Abstract JP-A-63-233916 English Abstract WO95 22970 English Abstract

Attached are copies of search report(s) from corresponding patent	
application(s), which are listed on the attached Submission Under MPEP 609.06.	
Attached are the following non-published pending patent applications	
which may be deemed relevant, which are listed on the attached Submission under	
MPEP 609.06.	
Please charge any deficiency or credit any overpayment to Deposit Account N	lo.
Respectfully submitted,	

/Samuel M. Kais, Reg.No. 42705/ Samuel M. Kais Reg. No. 42,705 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 Tel No.: 510-248-2363 DATED: September 30, 2010 Customer No. 27777